For tirzepatide, patients should be advised that oral contraceptive effectiveness may be reduced during initiation and dose escalation
Recommended testing schedule Baseline (before starting): Complete metabolic panel, CBC, lipid panel, HbA1c (even if not diabetic), B12, folate, vitamin D, thyroid panel, and fasting insulin
Veresiu AI, Bondor CI, Florea B, Vinik EJ, Vinik AI, Gvan NA
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
Higher doses may offer more immediate results but could also come with increased risks of side effects